192 related articles for article (PubMed ID: 31355134)
1. Impact of Taxanes, Endocrine Therapy, and Deleterious Germline
Lambertini M; Olympios N; Lequesne J; Calbrix C; Fontanilles M; Loeb A; Leheurteur M; Demeestere I; Di Fiore F; Perdrix A; Clatot F
Front Oncol; 2019; 9():575. PubMed ID: 31355134
[No Abstract] [Full Text] [Related]
2. Dose-dense FEC followed by docetaxel versus docetaxel plus cyclophosphamide as adjuvant chemotherapy in women with HER2-negative, axillary lymph node-positive early breast cancer: a multicenter randomized study by the Hellenic Oncology Research Group (HORG).
Mavroudis D; Matikas A; Malamos N; Papakotoulas P; Kakolyris S; Boukovinas I; Athanasiadis A; Kentepozidis N; Ziras N; Katsaounis P; Saloustros E; Georgoulias V;
Ann Oncol; 2016 Oct; 27(10):1873-8. PubMed ID: 27502729
[TBL] [Abstract][Full Text] [Related]
3. [Anti-Müllerian hormone as a new marker of the ovarian reserve function preservation by goserelin during (neo)adjuvant chemotherapy for young breast cancer patients].
Wang SY; Wang S
Beijing Da Xue Xue Bao Yi Xue Ban; 2019 Jun; 51(3):536-541. PubMed ID: 31209428
[TBL] [Abstract][Full Text] [Related]
4. Reproductive potential and performance of fertility preservation strategies in BRCA-mutated breast cancer patients.
Lambertini M; Goldrat O; Ferreira AR; Dechene J; Azim HA; Desir J; Delbaere A; t'Kint de Roodenbeke MD; de Azambuja E; Ignatiadis M; Demeestere I
Ann Oncol; 2018 Jan; 29(1):237-243. PubMed ID: 29045555
[TBL] [Abstract][Full Text] [Related]
5. Anthracycline could be essential for triple-negative breast cancer: A randomised phase II study by the Kanagawa Breast Oncology Group (KBOG) 1101.
Narui K; Ishikawa T; Shimizu D; Yamada A; Tanabe M; Sasaki T; Oba MS; Morita S; Nawata S; Kida K; Mogaki M; Doi T; Tsugawa K; Ogata H; Ota T; Kosaka Y; Sengoku N; Kuranami M; Niikura N; Saito Y; Suzuki Y; Suto A; Arioka H; Chishima T; Ichikawa Y; Endo I; Tokuda Y
Breast; 2019 Oct; 47():1-9. PubMed ID: 31229857
[TBL] [Abstract][Full Text] [Related]
6. Anti-Müllerian hormone (AMH) levels in premenopausal breast cancer patients treated with taxane-based adjuvant chemotherapy - A translational research project of the SUCCESS A study.
Trapp E; Steidl J; Rack B; Kupka MS; Andergassen U; Jückstock J; Kurt A; Vilsmaier T; de Gregorio A; de Gregorio N; Tzschaschel M; Lato C; Polasik A; Tesch H; Schneeweiss A; Beckmann MW; Fasching PA; Janni W; Müller V
Breast; 2017 Oct; 35():130-135. PubMed ID: 28732324
[TBL] [Abstract][Full Text] [Related]
7. Association of
Son KA; Lee DY; Choi D
Front Endocrinol (Lausanne); 2019; 10():235. PubMed ID: 31031710
[No Abstract] [Full Text] [Related]
8. Sequential adjuvant epirubicin-based and docetaxel chemotherapy for node-positive breast cancer patients: the FNCLCC PACS 01 Trial.
Roché H; Fumoleau P; Spielmann M; Canon JL; Delozier T; Serin D; Symann M; Kerbrat P; Soulié P; Eichler F; Viens P; Monnier A; Vindevoghel A; Campone M; Goudier MJ; Bonneterre J; Ferrero JM; Martin AL; Genève J; Asselain B
J Clin Oncol; 2006 Dec; 24(36):5664-71. PubMed ID: 17116941
[TBL] [Abstract][Full Text] [Related]
9. Increased chemotherapy-induced ovarian reserve loss in women with germline BRCA mutations due to oocyte deoxyribonucleic acid double strand break repair deficiency.
Oktay KH; Bedoschi G; Goldfarb SB; Taylan E; Titus S; Palomaki GE; Cigler T; Robson M; Dickler MN
Fertil Steril; 2020 Jun; 113(6):1251-1260.e1. PubMed ID: 32331767
[TBL] [Abstract][Full Text] [Related]
10. Impact of Cumulative Chemotherapy Dose on Survival With Adjuvant FEC-D Chemotherapy for Breast Cancer.
Veitch Z; Khan OF; Tilley D; Tang PA; Ribnikar D; Stewart DA; Kostaras X; King K; Lupichuk S
J Natl Compr Canc Netw; 2019 Aug; 17(8):957-967. PubMed ID: 31390594
[TBL] [Abstract][Full Text] [Related]
11. Weekly taxane-anthracycline combination regimen versus tri-weekly anthracycline-based regimen for the treatment of locally advanced breast cancer: a randomized controlled trial.
Tan QW; Luo T; Zheng H; Tian TL; He P; Chen J; Zeng HL; Lv Q
Chin J Cancer; 2017 Mar; 36(1):27. PubMed ID: 28270181
[TBL] [Abstract][Full Text] [Related]
12. Impact of adjuvant chemotherapy or tamoxifen-alone on the ovarian reserve of young women with breast cancer.
Goldfarb SB; Turan V; Bedoschi G; Taylan E; Abdo N; Cigler T; Bang H; Patil S; Dickler MN; Oktay KH
Breast Cancer Res Treat; 2021 Jan; 185(1):165-173. PubMed ID: 32930927
[TBL] [Abstract][Full Text] [Related]
13. Assessment of ovarian function after chemotherapy in women with early and locally advanced breast cancer from Serbia.
Malisic E; Susnjar S; Milovanovic J; Todorovic-Rakovic N; Kesic V
Arch Gynecol Obstet; 2018 Feb; 297(2):495-503. PubMed ID: 29101609
[TBL] [Abstract][Full Text] [Related]
14. Dose-dense paclitaxel versus docetaxel following FEC as adjuvant chemotherapy in axillary node-positive early breast cancer: a multicenter randomized study of the Hellenic Oncology Research Group (HORG).
Saloustros E; Malamos N; Boukovinas I; Kakolyris S; Kouroussis C; Athanasiadis A; Ziras N; Kentepozidis N; Makrantonakis P; Polyzos A; Christophyllakis C; Georgoulias V; Mavroudis D
Breast Cancer Res Treat; 2014 Dec; 148(3):591-7. PubMed ID: 25399229
[TBL] [Abstract][Full Text] [Related]
15. The Impact of Adding Taxanes to Anthracyclines on Women with Breast Cancer Receiving Adjuvant Chemotherapy.
Hilaj E; Ymeri A; Shpati KP
Cureus; 2020 Feb; 12(2):e7117. PubMed ID: 32257663
[TBL] [Abstract][Full Text] [Related]
16. Anti-Müllerian hormone serum concentrations of women with germline BRCA1 or BRCA2 mutations.
Phillips KA; Collins IM; Milne RL; McLachlan SA; Friedlander M; Hickey M; Stern C; Hopper JL; Fisher R; Kannemeyer G; Picken S; Smith CD; Kelsey TW; Anderson RA;
Hum Reprod; 2016 May; 31(5):1126-32. PubMed ID: 27094481
[TBL] [Abstract][Full Text] [Related]
17. Adjuvant chemotherapy in early breast cancer.
Ejlertsen B
Dan Med J; 2016 May; 63(5):. PubMed ID: 27127018
[TBL] [Abstract][Full Text] [Related]
18. Influence of adjuvant chemotherapy on anti-Müllerian hormone in women below 35 years treated for early breast cancer.
Perdrix A; Saint-Ghislain M; Degremont M; David M; Khaznadar Z; Loeb A; Leheurteur M; Di Fiore F; Clatot F
Reprod Biomed Online; 2017 Oct; 35(4):468-474. PubMed ID: 28652099
[TBL] [Abstract][Full Text] [Related]
19. BRCA1/2 gene mutations do not affect the capacity of oocytes from breast cancer candidates for fertility preservation to mature in vitro.
Grynberg M; Dagher Hayeck B; Papanikolaou EG; Sifer C; Sermondade N; Sonigo C
Hum Reprod; 2019 Feb; 34(2):374-379. PubMed ID: 30561604
[TBL] [Abstract][Full Text] [Related]
20. A prospective longitudinal analysis of the predictors of amenorrhea after breast cancer chemotherapy: Impact of BRCA pathogenic variants.
Oktay KH; Turan V; Bedoschi G; Abdo N; Bang H; Goldfarb S
Cancer Med; 2023 Sep; 12(18):19225-19233. PubMed ID: 37698031
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
